Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

BACKGROUND: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC) concentrations of tenofovir disoproxil fumarate (TDF), by...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Andrew, Hughes, Sophie L, Gotham, Dzintars, Pozniak, Anton L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mediscript Ltd 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892670/
https://www.ncbi.nlm.nih.gov/pubmed/29682298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892670/
https://www.ncbi.nlm.nih.gov/pubmed/29682298

Ejemplares similares